Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baudax Bio Inc BXRXQ

Healthcare
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in... see more

Recent & Breaking News (PINL:BXRXQ)

Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®

GlobeNewswire March 2, 2022

Baudax Bio Announces Pricing of $10.0 Million Public Offering

GlobeNewswire February 24, 2022

Baudax Bio Announces Proposed Public Offering of Securities

GlobeNewswire February 24, 2022

Baudax Bio Announces 1-for-35 Reverse Stock Split

GlobeNewswire February 15, 2022

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

GlobeNewswire January 4, 2022

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 31, 2021

Baudax Bio Announces $4.2 Million Registered Direct Offering

GlobeNewswire December 28, 2021

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 15, 2021

Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000

GlobeNewswire November 11, 2021

Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire November 4, 2021

Baudax Bio to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

GlobeNewswire October 28, 2021

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

GlobeNewswire October 5, 2021

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 1, 2021

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 16, 2021

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights

GlobeNewswire August 5, 2021

Baudax Bio Announces Date of Reconvened Special Meeting

GlobeNewswire July 30, 2021

Baudax Bio to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

GlobeNewswire July 29, 2021

Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote "For" the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

GlobeNewswire July 1, 2021

Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote "For" the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

GlobeNewswire June 30, 2021